Diffuse large B cell lymphoma liquid biopsy study

UK NEQAS LI will be running a small study where laboratories will be requested to detect and quantify any pathogenic intragenic and/or regulatory element changes such as point mutations, small insertion, deletion and duplications events down to MRD present in cell free DNA (cfDNA), standardly in blood plasma, but occasionally in other bodily fluids e.g. cerebrospinal fluid, used to manage patients with lymphoma. A diagnostic clinical scenario will be provided to inform participants of what trackable markers were detected at diagnosis.  admin@ukneqasli.co.uk

Print | Sitemap

Follow Us Online
Facebook Twitter LinkedIn Youtube


Last updated 14/06/2024 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information please click here.

Please click here for our privacy policy.

The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).